Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor

The outlook for T-cell malignancies remain poor due to the lack of effective therapeutic options. Chimeric antigen receptor (CAR) immunotherapy has recently shown promise in clinical trials for B-cell malignancies, however, designing CARs for T-cell based disease remain a challenge due to the shared...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, K H, Wada, M, Pinz, K G, Liu, H, Lin, K-W, Jares, A, Firor, A E, Shuai, X, Salman, H, Golightly, M, Lan, F, Senzel, L, Leung, E L, Jiang, X, Ma, Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629371/
https://www.ncbi.nlm.nih.gov/pubmed/28074066
http://dx.doi.org/10.1038/leu.2017.8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629371/
https://www.ncbi.nlm.nih.gov/pubmed/28074066
http://dx.doi.org/10.1038/leu.2017.8

Ejemplares similares